- Open Access
Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)
© The Author(s). 2018
- Received: 17 May 2018
- Accepted: 3 September 2018
- Published: 27 September 2018
There are currently no treatments for empathy deficits in neuropsychiatric disorders. Acute administration of the hormone oxytocin has been associated with symptomatic improvements across animal models and several neuropsychiatric disorders, but results of the majority of oxytocin randomised controlled trials (RCTs) of longer duration have been negative or inconclusive. This lack of efficacy of may be due to rapid habituation to oxytocin with chronic dosing. The objective of the present study is to describe the design of a phase 2 adaptive randomised controlled crossover trial of intranasal oxytocin in frontotemporal dementia (FOXY) as an efficient model for future investigations of symptomatic treatments in neuropsychiatric and neurodegenerative disorders.
Stage 1 will identify which of three dose schedules is most promising based on change in the primary outcome measure, the Neuropsychiatric Inventory apathy/indifference domain score, over 6 weeks of treatment. In stage 2, additional patients are enrolled at the most promising dose for preliminary efficacy analysis when combined with stage 1 to determine if a phase 3 trial is warranted. Objective measures include facial expression recognition, cerebrospinal fluid (CSF) oxytocin levels, and behavioural ratings of videotaped interactions.
A total of 20 patients per arm will be entered into stage 1 for a total of 60 patients. In stage 2, an additional 40 patients will be enrolled in the most promising dose arm.
The use of adaptive, crossover designs and inclusion of objective measures of change in CSF oxytocin levels and social behaviour will improve the efficiency and conclusiveness of RCTs of oxytocin and other symptomatic treatments in neuropsychiatric disorders.
ClinicalTrials.gov, NCT03260920. Registered on August 24, 2017.
- Frontotemporal dementia
- Adaptive design
- Crossover design
- Clinical trial
Social apathy and loss of empathy are hallmark features of frontotemporal dementia (FTD), for which there are currently no approved or effective treatments. Oxytocin, a neuropeptide modulating social behaviour across species, has been identified as a potential symptomatic therapy for empathy and related social behaviour impairments across neuropsychiatric conditions . However, to date, the evidence supporting the long-term use of oxytocin is lacking. Identification of effective, evidence-based symptomatic treatments for social cognition and behaviour deficits in FTD and other neuropsychiatric disorders raises several unique challenges for clinical trial design and implementation. These challenges include symptom and behavioural heterogeneity, the nonlinear trajectory of many behavioural symptoms over the course of the disease, lack of harmonisation of assessment and outcome measures across centres, and reliance on subjective caregiver reports for key outcome measures [2–4]. Additional challenges for randomised controlled trials (RCTs) of oxytocin include potential differential responses according to sex, uncertainties around brain penetration of intranasal formulations, lack of dose-finding studies, and confirmation of target engagement .
Further, specific to oxytocin, although numerous published reports cite improvements in social cognition in several disorders following single-dose administration [6–8], longer-duration (2–6 weeks) RCTs of oxytocin have had mixed results, with several showing no or small effects [9–13]. These trials have used once- or twice-daily dose schedules and have not included design elements to address the potential habituation of responses with chronic dosing that has been reported in non-human animal studies [14–17]. In patients with FTD, short-term administration of oxytocin was associated with improvement in caregiver ratings of social behaviours and effects of emotional facial expression recognition [18, 19], though longer-term studies have not yet been conducted. A formal dose-finding study in FTD identified 72 IU twice daily as the most feasible dose, a dose larger than that used in the majority of oxytocin RCTs in other disorders .
To address the lack of specific symptomatic treatment in FTD and limitations of oxytocin and related trial designs targeting social behaviours across a range of disorders to date, we describe a novel adaptive proof-of-concept, phase 2, placebo-controlled, randomised crossover trial repurposing the hormone and neuropeptide oxytocin as a potential symptomatic treatment for apathy/indifference and related empathy deficits in patients with FTD. The objectives of the study design are to (1) efficiently identify the most promising dose schedule of oxytocin, given potential habituation to daily dosing, and (2) permit efficacy analysis of the most promising dose compared with placebo to determine whether progression to a phase 3 trial is warranted. We propose that this approach may inform the design and conduct of other RCTs, particularly of symptomatic medications in FTD and related neuropsychiatric disorders.
Participants with a diagnosis of probable FTD (behavioural variant FTD, FTD semantic subtype or FTD progressive non-fluent aphasia) [20, 21] with current symptoms of social apathy/indifference as measured by Neuropsychiatric Inventory (NPI) apathy/indifference severity subscale score ≥ 2 , supportive brain imaging based on centrally rated frontotemporal atrophy score of ≥ 2 based on brain magnetic resonance imaging or computed tomography  or FTD pattern of hypometabolism on fluorodeoxyglucose positron emission tomography or hypoperfusion on single-photon emission computed tomography, or known causal genetic mutation, and a caregiver who sees the patient daily for at least 3 h/d and who can administer all trial medications are eligible for the study. Additional inclusion criteria include a frontotemporal lobar degeneration Clinical Dementia Rating (FTLD-CDR)  score consistent with mild or moderate dementia, Mini Mental State Examination score > 10/30, and stable baseline medications for ≥ 30 days. Exclusion criteria include recent myocardial infarction, congestive heart failure, current uncontrolled hypertension, bradycardia, long QTc or hyponatremia. Participants will be enrolled at one of ten FTD centres in the United States and Canada comprising the Advancing Research & Treatment for Frontotemporal Lobar Degeneration network (www.rarediseasesnetwork.org/cms/artfl) plus three additional Canadian sites.
Randomisation for stages 1 and 2 will be stratified across the treatment groups listed above according to sex and disease severity (mild vs. moderate) because oxytocin is known to have differential behavioural effects based on sex , and pilot data suggest that efficacy may differ as a function of disease severity and the integrity of remaining oxytocin receptor-positive neurons [19, 30]. The FTLD-CDR allows severity assessment and stratification across the different FTD phenotypes included in the trial. The number of centres required for the trial precludes stratification according to centre. Participants will be randomised using variable block sizes concealed from participating sites.
Outcome measures and minimum clinically significant difference
Outcome assessments completed at baseline assessment, end of treatment period 1, after washout (baseline 2), and end of treatment period 2
Primary outcome measure:
• Neuropsychiatry Inventory (NPI) apathy/indifference domain score 
Secondary outcome measures:
• Interpersonal Reactivity Index (IRI) empathic concern scale and total score 
• Emotional facial expression recognition performance 
• Revised Self-Monitoring Scale (RSMS) score 
• NPI caregiver distress scores on NPI apathy/indifference scale and total caregiver distress scores 
• Total NPI scores
• Cambridge Behavioural Inventory 
• Addenbrooke’s Cognitive Examination III 
• Social Observation Checklist blinded central ratings of videotaped meals with patients and caregivers .
Data analysis and pre-specification of adaptive design decision algorithms
At the completion of stage 1 the analysis described below will take place to select the most promising dose schedule that will show the largest estimated mean change (benefit) of oxytocin relative to placebo on the primary outcome measure, the NPI apathy/indifference domain scale scores. A linear model with covariates for sex and order of treatment in the crossover will be used to estimate the efficacy of each treatment arm. Each patient will have a 6-week post-treatment change from baseline score for each treatment phase (i.e., week 6 − week 0 vs. week 18 − week 12). The within-patient difference in these values ‘on active’ vs. ‘on placebo’, Y, will be modelled assuming a normal linear model: Y~N(θt + β1X1 + β2X2, σ2), where X1 is an indicator of the patient having the active as the first treatment in the crossover and X2 an indicator of the patient being a male. The efficacy of the three active treatment arms are captured by the mean change in total NPI apathy/indifference treatment parameters, θ1, θ2, and θ3.
The treatment arm with the largest estimated mean change (benefit) will be selected for stage 2. Note that the dosing strategy selection analysis does not depend on a formal hypothesis test. If two or more dose schedules appear equally promising (i.e., similar estimated mean change), consideration of side effect profile can be used to select the most promising and tolerable dose schedule. If two or more dose schedules appear equally promising and their side effect profiles are similar, the more frequent dose schedule will be selected in stage 2. Enrolment in the groups and subgroups is relatively small, and important information may be gained by CSF oxytocin measurements as well as secondary outcome measures to inform future studies, thus no futility analysis will be conducted at the end of stage 1.
Given the crossover design and proof-of-concept nature of the study, a variant of a per-protocol analysis will be conducted on the patients completing the protocol, defined as those who entered into both phases of the treatment, have a primary outcome measure, and took ≥ 70% of sprays. A modified intention-to-treat analysis will be conducted as a supportive analysis, including all patients who were randomised and received at least one dose of study drug. Because the primary outcome measure can be obtained via telephone interview with the caregiver, wherever available, this will be collected for patients who do not complete the study, with the last observation carried forward.
Sample size justification
Primary outcome measure
Sample size and clinical trial simulations were based on a published pilot study of oxytocin in FTD and designated minimal clinically significant difference of 2 points on the NPI apathy/indifference score . Simulations were conducting using the Fixed and Adaptive Clinical Trial Simulator (www.berryconsultants.com) and varying the number of patients and effect sizes in stage 1 to show the operating characteristics. The simulations assumed an SD of 3.3 between the placebo and active arms (based on prior published studies of mean differences and SD on the NPI for an individual patient) . Differences from 0 to 3 in the effect of an arm relative to placebo were explored for each trial design. For each design scenario 10,000 simulated trials were conducted. These simulations demonstrate that for a mean difference of 2 points or more from placebo, a sample size of 54 patients receiving the target dose schedule has an 86% probability of showing superiority to placebo at the end of stage 2 (Additional file 1). To enrol at least 54 patients in the target dose schedule, a total of 100 patients will be enrolled in this trial. In stage 1, 20 patients with FTD will be randomised to each of the three arms (daily, alternate days, or third-day dosing). In stage 2, an additional 40 patients will be randomised to the target dose schedule, resulting in a sample size of 60 patients at the target dose schedule across both study phases. With enrolment of 60 patients (30 males and 30 females) in the target dose schedule, subgroup analysis based on sex will have a power of 80% to detect a 2-point difference on the NPI apathy domain based on within-patient SD of differences of 3.3 in our pilot study  and will permit up to 15% loss of data due to potential non-compliance or loss to follow-up. For the main secondary outcome measure of interest, the empathic concern scale of the IRI, based on an SD of the change from baseline of 1.75 , a sample of 20 patients per arm per sex provides power of 80% to detect a 1-point difference.
Following a study of a single dose of 24 IU intranasal oxytocin in which researchers found statistically significant increases in the adult volunteers’ CSF oxytocin measured at 75 min (+ 64%) , using paired t tests, a sample of 10 participants from the daily oxytocin dose schedule group provides power > 0.95 to detect a significant difference in CSF oxytocin levels after 6 weeks of oxytocin vs. placebo treatment.
The proposed trial represents an application of an adaptive crossover Bayesian design to improve the efficiency of determining the efficacy of symptomatic treatment for FTD. Specifically, and building on the Co-Enzyme Q10 in Amyotrophic Lateral Sclerosis study , the two-stage design permits dose schedule selection and efficacy assessment with a smaller sample size than traditional designs. The design addresses potential limitations of prior RCTs evaluating the effects of oxytocin on behaviour in other neuropsychiatric disorders by use of a crossover design, inclusion of an objective rating of videotaped naturalistic behaviours during each treatment phase, and measurements of CSF oxytocin levels to confirm entry of drug into the CNS. Inclusion of symptom-specific and global measures of caregiver distress will enable identification of meaningful clinical change for each measure for the present study as well as future interventional studies.
Efficiencies in sample size of adaptive crossover trial compared with traditional and parallel trial designs
Sample size dose selectiona
Sample size POC efficacy
Total sample size
Traditional parallel armb
Recent RCTs of intranasal oxytocin for social cognition deficits in autistic spectrum disorders have had mixed results [3, 10]. Indications that caregiver assessments of change in behaviour are strongly correlated with assumptions about treatment status  have led the National Institute of Mental Health to specify that objective measures of treatment response should be included in studies of oxytocin in patient populations . Given the lack of insight in patients with FTD and reliance on caregiver judgments regarding behavioural change, the same potential confound exists for behavioural outcome measures in FTD. Recent development and validation of the Social Observation Checklist using videotaped encounters between patients and caregivers during meals  provides an objective means by which to quantify naturalistic behaviours and reduce site-related variability by use of a blinded central rater. Use of a crossover design is also important in disorders such as FTD, where caregiver measurements are an important outcome measure and when significant subject-to-subject symptom heterogeneity is present. For example, all patients enrolled will meet inclusion criteria for social apathy and empathy deficits, the main behavioural symptoms potentially impacted by oxytocin, but patients are expected to have different combinations of other FTD behavioural symptoms (i.e., impulsivity, obsessive-compulsive behaviours, aggression) which could differentially interact with the effects of interest. The crossover allows the analysis to account for the subject-to-subject heterogeneity explicitly, greatly reducing the SD across subjects. Inclusion of oxytocin CSF measurements will provide needed data to determine whether CSF level changes correlate with behavioural changes, and thus inform dosing strategies. In the event that the clinical outcomes are positive, these data may help to refine dose selection for a phase 3 trial. In the event that there is no efficacy signal, the data would confirm that sufficient drug reached the CNS and therefore would support a negative (as opposed to inconclusive) result for oxytocin.
Currently, a direct measure of oxytocin target engagement in humans is limited by the lack of an available positron emission tomography tracer. Although the CSF measurements should aid in distinction between a negative trial and an inconclusive trial due to lack of drug in the CNS, it is possible that oxytocin levels may rise in specific brain regions proximal to the site of administration (basal forebrain, ventral frontal and mesial temporal lobes) or secondary to trigger of endogenous oxytocin release without significant rises in CSF . However, if CSF oxytocin levels do not show measurement increases and the objective performance measures do not show efficacy, this would indicate that a phase 3 trial in FTD is not warranted. The present study will also address whether a 2-point improvement on the NPI, which has been used in prior clinical trials [31, 41], reflects a clinically significant reduction in caregiver distress. These critical indicators of the value of potential treatments for FTD will be assessed with the NPI caregiver distress scores. If results of this RCT are positive, knowledge of how a change in NPI scores corresponds to caregiver distress scores will critically inform designation of a minimal clinically significant difference for a phase 3 trial and FTD more globally.
Adaptive design and crossover trials are uncommon designs in clinical trials in dementia. Building on the use of adaptive trial designs to assess potential neuroprotective treatments in neurodegenerative disorders , we describe an application of an adaptive crossover design to facilitate dose selection and efficacy assessment for symptomatic treatment in FTD. The design and inclusion of objective measures to index outcomes related to behaviour and emotion can be applied to study of oxytocin and other symptom-focused treatments in other neuropsychiatric and neurodegenerative disorders.
This trial is funded by peer-reviewed grants from the Weston Foundation and the Canadian Institutes of Health Research.
Availability of data and materials
Not applicable, because this article describes a novel trial design.
All authors contributed to the study design and critical review of the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study has received a no objection letter from Health Canada and investigational new drug approval from the FDA. Ethics approvals will be obtained at each participating site.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Insel TR. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron. 2010;65(6):768–79.View ArticleGoogle Scholar
- Knopman DS, Boeve BS, Caselli RJ, Graff-Radford NR, Kramer JH, Mendez MF, Miller BL. Longitudinal tracking of FTLD: toward developing clinical trial methodology. Alzheimer Dis Assoc Disord. 2007;21(4):S58–63.View ArticleGoogle Scholar
- Guastella AJ, Gray KM, Rinehart NJ, Alvares GA, Tonge BJ, Hickie IB, Keating CM, Cacciotti-Saija C, Einfeld SL. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry. 2015;56(4):444–52.View ArticleGoogle Scholar
- Miller JB, Banks SJ, Leger GC, Cummings JL. Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes. Transl Neurodegener. 2014;3:12.View ArticleGoogle Scholar
- Insel TR. Translating oxytocin neuroscience to the clinic: a National Institute of Mental Health perspective. Biol Psychiatry. 2016;79(3):153–4.View ArticleGoogle Scholar
- Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. Oxytocin improves “mind-reading” in humans. Biol Psychiatry. 2007;61(6):731–3.View ArticleGoogle Scholar
- Guastella AJ, Mitchell PB, Dadds MR. Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry. 2008;63(1):3–5.View ArticleGoogle Scholar
- Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007;61(4):498–503.View ArticleGoogle Scholar
- Einfeld SL, Smith E, McGregor IS, Steinbeck K, Taffe J, Rice LJ, Horstead SK, Rogers N, Hodge MA, Guastella AJ. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome. Am J Med Genet A. 2014;164A(9):2232–9.View ArticleGoogle Scholar
- Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry. 2016;21(9):1225–31.View ArticleGoogle Scholar
- Cacciotti-Saija C, Langdon R, Ward PB, Hickie IB, Scott EM, Naismith SL, Moore L, Alvares GA, Redoblado Hodge MA, Guastella AJ. A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophr Bull. 2015;41(2):483–93.View ArticleGoogle Scholar
- Gibson CM, Penn DL, Smedley KL, Leserman J, Elliott T, Pedersen CA. A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophr Res. 2014;156(2–3):261–5.View ArticleGoogle Scholar
- Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S, Wang AT, Pepa L, Tanel N, Kushki A, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012;3(1):16.View ArticleGoogle Scholar
- Bales KL, Perkeybile AM, Conley OG, Lee MH, Guoynes CD, Downing GM, Yun CR, Solomon M, Jacob S, Mendoza SP. Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles. Biol Psychiatry. 2013;74(3):180–8.View ArticleGoogle Scholar
- Huang H, Michetti C, Busnelli M, Manago F, Sannino S, Scheggia D, Giancardo L, Sona D, Murino V, Chini B, et al. Chronic and acute intranasal oxytocin produce divergent social effects in mice. Neuropsychopharmacology. 2014;39(5):1102–14.View ArticleGoogle Scholar
- Conti F, Sertic S, Reversi A, Chini B. Intracellular trafficking of the human oxytocin receptor: evidence of receptor recycling via a Rab4/Rab5 “short cycle”. Am J Physiol Endocrinol Metab. 2009;296(3):E532–42.View ArticleGoogle Scholar
- Peters S, Slattery DA, Uschold-Schmidt N, Reber SO, Neumann ID. Dose-dependent effects of chronic central infusion of oxytocin on anxiety, oxytocin receptor binding and stress-related parameters in mice. Psychoneuroendocrinology. 2014;42:225–36.View ArticleGoogle Scholar
- Jesso S, Morlog D, Ross S, Pell MD, Pasternak SH, Mitchell DG, Kertesz A, Finger EC. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain. 2011;134(Pt 9):2493–501.View ArticleGoogle Scholar
- Finger EC, MacKinley J, Blair M, Oliver LD, Jesso S, Tartaglia MC, Borrie M, Wells J, Dziobek I, Pasternak S, et al. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Neurology. 2015;84(2):174–81.View ArticleGoogle Scholar
- Rascovsky K, Hodges JR, Kipps CM, Johnson JK, Seeley WW, Mendez MF, Knopman D, Kertesz A, Mesulam M, Salmon DP, et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord. 2007;21(4):S14–8.View ArticleGoogle Scholar
- Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–14.View ArticleGoogle Scholar
- Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10–6.View ArticleGoogle Scholar
- Kipps CM, Davies RR, Mitchell J, Kril JJ, Halliday GM, Hodges JR. Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dement Geriatr Cogn Disord. 2007;23(5):334–42.View ArticleGoogle Scholar
- Kertesz A, Davidson W, Fox H. Frontal Behavioral Inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci. 1997;24(1):29–36.View ArticleGoogle Scholar
- Day GS, Farb NA, Tang-Wai DF, Masellis M, Black SE, Freedman M, Pollock BG, Chow TW. Salience network resting-state activity: prediction of frontotemporal dementia progression. JAMA Neurol. 2013;70(10):1249–53.PubMedGoogle Scholar
- Striepens N, Kendrick KM, Hanking V, Landgraf R, Wullner U, Maier W, Hurlemann R. Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep. 2013;3:3440.View ArticleGoogle Scholar
- Chang SW, Barter JW, Ebitz RB, Watson KK, Platt ML. Inhaled oxytocin amplifies both vicarious reinforcement and self reinforcement in rhesus macaques (Macaca mulatta). Proc Natl Acad Sci U S A. 2012;109(3):959–64.View ArticleGoogle Scholar
- Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci. 2002;5(6):514–6.View ArticleGoogle Scholar
- Nakajima M, Gorlich A, Heintz N. Oxytocin modulates female sociosexual behavior through a specific class of prefrontal cortical interneurons. Cell. 2014;159(2):295–305.View ArticleGoogle Scholar
- Diodati D, Cyn-Ang L, Kertesz A, Finger E. Pathologic evaluation of the supraoptic and paraventricular nuclei in dementia. Can J Neurol Sci. 2012;39(2):213–9.View ArticleGoogle Scholar
- Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, Mendez M, Kerwin D, Lerner A, Wu CK, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(2):149–56.View ArticleGoogle Scholar
- Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004;363(9427):2105–15.View ArticleGoogle Scholar
- Davis MH. A multidimensional approach to individual differences in empathy. JSAS Catalog of Selected Documents in Psychology 1980.Google Scholar
- Lennox RD, Wolfe RN. Revision of the Self-Monitoring Scale. J Pers Soc Psychol. 1984;46(6):1349–64.View ArticleGoogle Scholar
- Mendez MF, Fong SS, Shapira JS, Jimenez EE, Kaiser NC, Kremen SA, Tsai PH. Observation of social behavior in frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2012;29(3):215–21.View ArticleGoogle Scholar
- Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, Battista V, Zhou X, Mitsumoto H, Levin B, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006;66(5):660–3.View ArticleGoogle Scholar
- Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27–36.View ArticleGoogle Scholar
- Meurer WJ, Lewis RJ, Tagle D, Fetters MD, Legocki L, Berry S, Connor J, Durkalski V, Elm J, Zhao W, et al. An overview of the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project. Ann Emerg Med. 2012;60(4):451–7.View ArticleGoogle Scholar
- Young LJ, Barrett CE. Can oxytocin treat autism? Science. 2015;347(6224):825–6.View ArticleGoogle Scholar
- Leng G, Ludwig M. Intranasal oxytocin: myths and delusions. Biol Psychiatry. 2016;79(3):243–50.View ArticleGoogle Scholar
- Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676–85.View ArticleGoogle Scholar
- Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308.View ArticleGoogle Scholar
- Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord. 1997;11:22–32.View ArticleGoogle Scholar
- Lanctôt KL, Chau SA, Herrmann N, Drye LT, Rosenberg PB, Scherer RW, Black SE, Vaidya V, Bachman DL, Mintzer JE. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. Int Psychogeriatr. 2014;26(02):239–46.View ArticleGoogle Scholar
- Lennox RD, Wolfe RN: Revision of the Self-Monitoring Scale. 1984.Google Scholar
- Bozeat S, Gregory CA, Ralph MAL, Hodges JR. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer’s disease? J Neurol Neurosurg Psychiatry. 2000;69(2):178–86.View ArticleGoogle Scholar
- Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke’s Cognitive Examination III in frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord. 2013;36(3–4):242–50.View ArticleGoogle Scholar